Stifel Financial Corp Mannkind Corp Transaction History

Stifel Financial Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.67 - $4.77 $109,360 - $195,374	-40,959 Reduced 35.9%	73,134 $279,000
Q1 2022 May 13, 2022	BUY	$2.62 - $4.45 $14,989 - $25,458	5,721 Added 5.28%	114,093 $420,000
Q4 2021 Feb 14, 2022	BUY	$4.05 - $5.37 $63,240 - $83,852	15,615 Added 16.83%	108,372 $474,000
Q3 2021 Nov 15, 2021	SELL	$3.89 - $5.48 $19,625 - $27,646	-5,045 Reduced 5.16%	92,757 $403,000
Q2 2021 Aug 13, 2021	SELL	$3.61 - $5.45 $8,339 - $12,589	-2,310 Reduced 2.31%	97,802 $533,000
Q1 2021 May 14, 2021	BUY	$3.14 - $6.14 $192,799 - $377,002	61,401 Added 158.61%	100,112 $392,000
Q4 2020 Feb 12, 2021	BUY	$1.79 - $4.04 $69,292 - $156,392	38,711 New	38,711 $121,000

244

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.57B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.